quinoxalines has been researched along with oxidopamine in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 18 (62.07) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 6 (20.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunow, M; Löschmann, PA; Wachtel, H | 2 |
| Reid, A; Sawynok, J | 1 |
| Levine, JD; Taiwo, YO | 1 |
| Honoré, T; Jähnig, P; Jenner, P; Kunow, M; Lange, KW; Löschmann, PA; Marsden, CD; Rettig, KJ; Turski, L; Wachtel, H | 1 |
| Atgie, C; Carpene, C; Lafontan, M; Quideau, N; Saulnier-Blache, JS | 1 |
| Hyman, AL; Kadowitz, PJ; Lippton, HL | 1 |
| Kemmotsu, O; Matsumoto, M; Numazawa, R; Saito, H; Togashi, H; Yoshioka, M | 1 |
| Bennett, JP; Richard, MG | 1 |
| Carta, A; Fenu, S; Morelli, M | 1 |
| Anderson, JJ; Boldry, RC; Chase, TN; Engber, TM; Kuo, S; Papa, SM | 1 |
| Frankenschmidt, A; Rump, LC; Schaible, U; Schollmeyer, PJ; Schuster, MJ; Schwertfeger, E | 1 |
| Bernardi, G; Calabresi, P; Mercuri, NB; Sancesario, G | 1 |
| Greenamyre, JT | 1 |
| Anzilotti, KF; Jackson, PF; Rissolo, KC; Stauch Slusher, B | 1 |
| Marshall, JF; Schuller, JJ | 2 |
| Oriowo, MA; Williams, KI; Yousif, M | 1 |
| Heneka, MT; Klockgether, T; Kunow, M; Löschmann, PA; Schulz, JB; Wachtel, H; Wüllner, U | 1 |
| Chopin, P; Colpaert, FC; Marien, M | 1 |
| Adler-Graschinsky, E; Boric, MP; Figueroa, XF; Huidobro-Toro, JP; Mendizábal, VE; Poblete, MI | 1 |
| Auberson, YP; Fantin, M; Morari, M | 1 |
| Ilijic, E; Surmeier, DJ; Taverna, S | 1 |
| Ali, U; Chen, L; Gui, ZH; Hui, YP; Li, Q; Liu, J; Wang, T; Wang, Y; Zhang, QJ | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
| Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C | 1 |
| Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R | 1 |
| Avegno, EM; Borgkvist, A; Hen, R; Kheirbek, MA; Sonders, MS; Sulzer, D; Wong, MY | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del Bel, E; Dos-Santos-Pereira, M; Padovan-Neto, FE; Raisman-Vozari, R; Tumas, V | 1 |
1 review(s) available for quinoxalines and oxidopamine
| Article | Year |
|---|---|
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Evaluation, Preclinical; Drug Synergism; Drug Tolerance; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Haplorhini; Humans; Mice; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, Dopamine; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1993 |
28 other study(ies) available for quinoxalines and oxidopamine
| Article | Year |
|---|---|
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Apomorphine; Dopamine Agents; Drug Synergism; Ibotenic Acid; Lisuride; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical | 1992 |
Noradrenergic mediation of spinal antinociception by 5-hydroxytryptamine: characterization of receptor subtypes.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Antagonists; Amphetamines; Animals; Desipramine; In Vitro Techniques; Male; Nociceptors; Norepinephrine; Oxidopamine; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists; Spinal Cord | 1992 |
Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Drug Synergism; Lisuride; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Wistar; Stereotaxic Techniques; Substantia Nigra | 1992 |
Serotonin is a directly-acting hyperalgesic agent in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dose-Response Relationship, Drug; Hydroxyurea; Hyperalgesia; Indomethacin; Male; Nociceptors; Oxidopamine; Pain; Quinoxalines; Rats; Rats, Inbred Strains; Reflex; Sensory Thresholds; Serotonin; Serotonin Antagonists; Tetrahydronaphthalenes | 1992 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Callithrix; Disease Models, Animal; Drug Synergism; Ibotenic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1991 |
Hamster adipocyte alpha 2-adrenoceptor changes during fat mass modifications are not directly dependent on adipose tissue norepinephrine content.
Topics: Adipose Tissue; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Cricetinae; Dioxanes; Energy Intake; Food Deprivation; Hydroxydopamines; Idazoxan; Lipolysis; Male; Mesocricetus; Norepinephrine; Oxidopamine; Pindolol; Quinoxalines; Receptors, Adrenergic, alpha; Sympathectomy, Chemical | 1990 |
Nature of alpha 1 and postjunctional alpha 2 adrenoceptors in the pulmonary vascular bed.
Topics: Animals; Azepines; Blood Pressure; Brimonidine Tartrate; Cats; Hydroxydopamines; Methoxamine; Norepinephrine; Oxidopamine; Phenylephrine; Prazosin; Propranolol; Pulmonary Artery; Quinoxalines; Receptors, Adrenergic, alpha; Vasoconstriction; Yohimbine | 1986 |
Pharmacological characterization of alpha 2-adrenoceptor regulated serotonin release in the rat hippocampus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Brimonidine Tartrate; Dioxanes; GTP-Binding Proteins; Hippocampus; Idazoxan; Imidazoles; Male; Oxidopamine; Pertussis Toxin; Potassium; Quinoxalines; Rats; Rats, Wistar; Second Messenger Systems; Serotonin; Tetrodotoxin; Virulence Factors, Bordetella | 1995 |
NMDA receptor blockade increases in vivo striatal dopamine synthesis and release in rats and mice with incomplete, dopamine-depleting, nigrostriatal lesions.
Topics: Animals; Arginine; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Excitatory Amino Acids; Male; Mice; Microdialysis; Nitroarginine; Oxidopamine; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Valine | 1995 |
Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dizocilpine Maleate; Immunohistochemistry; Injections; Male; Neostriatum; Oxidopamine; Piperazines; Proto-Oncogene Proteins c-fos; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical | 1995 |
Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Autoradiography; Brain; Carbon Radioisotopes; Deoxyglucose; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Organ Specificity; Oxidopamine; Quinoxalines; Rats; Rats, Sprague-Dawley | 1994 |
Dopamine DA2-receptor activation inhibits noradrenaline release in human kidney slices.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Brimonidine Tartrate; Calcium; Dopamine Agents; Ergolines; Fenoldopam; Humans; In Vitro Techniques; Indoles; Kidney Cortex; Middle Aged; Norepinephrine; Oxidopamine; Pyridines; Quinoxalines; Quinpirole; Receptors, Dopamine D2; Sulpiride; Tetrodotoxin | 1993 |
Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Ergolines; Male; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Quinpirole; Rats; Rats, Wistar; Substantia Nigra; Synaptic Membranes; Tetrodotoxin | 1993 |
Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Excitatory Amino Acid Antagonists; Male; Mesencephalon; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra | 1995 |
Intrastriatal DNQX induces rotation and pallidal Fos in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Quinoxalines; Rats; Rats, Sprague-Dawley; Rotation | 1995 |
Characterization of alpha-adrenoceptor subtype(s) mediating vasoconstriction in the perfused rabbit ovarian vascular bed.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Dose-Response Relationship, Drug; Electric Stimulation; Female; Ovary; Oxidopamine; Perfusion; Prazosin; Quinoxalines; Rabbits; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Vasoconstriction | 1996 |
Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agonists; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior | 1997 |
Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Apomorphine; Behavior, Animal; Benzofurans; Brimonidine Tartrate; Clonidine; Dopamine Agonists; Idazoxan; Imidazoles; Ligands; Male; Methylphenidate; Oxidopamine; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Stereoisomerism; Stereotyped Behavior; Substantia Nigra | 1999 |
Acute immediate-early gene response to 6-hydroxydopamine infusions into the medial forebrain bundle.
Topics: Animals; Basal Ganglia; Behavior, Animal; Excitatory Amino Acid Antagonists; Gene Expression; Genes, Immediate-Early; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sensation; Time Factors | 2000 |
Clonidine-induced nitric oxide-dependent vasorelaxation mediated by endothelial alpha(2)-adrenoceptor activation.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Acetylcholine; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Clonidine; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Guanylate Cyclase; In Vitro Techniques; Mesenteric Arteries; Nitric Oxide; Nitroarginine; Oxadiazoles; Oxidopamine; Phenylephrine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Saponins; Sildenafil Citrate; Solubility; Sulfones; Sympatholytics; Time Factors; Vascular Resistance; Vasodilation; Vasodilator Agents; Yohimbine | 2001 |
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonists; Globus Pallidus; Male; Microdialysis; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley | 2008 |
Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease.
Topics: Animals; Animals, Newborn; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Green Fluorescent Proteins; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Medial Forebrain Bundle; Mice; Mice, Transgenic; Nerve Net; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Quinoxalines; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics; Synapses | 2008 |
Noradrenergic lesion of the locus coeruleus increases the firing activity of the medial prefrontal cortex pyramidal neurons and the role of alpha2-adrenoceptors in normal and medial forebrain bundle lesioned rats.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Locus Coeruleus; Male; Medial Forebrain Bundle; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Pyramidal Cells; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Yohimbine | 2010 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles | 2012 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2013 |
Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.
Topics: Adrenergic Agents; Animals; Bacterial Proteins; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; GABA Agents; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Inhibitory Postsynaptic Potentials; Luminescent Proteins; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Pyridinium Compounds; Quaternary Ammonium Compounds; Quinoxalines; Substantia Nigra | 2015 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Quinoxalines; Rats, Wistar; Signal Transduction | 2019 |